nodes	percent_of_prediction	percent_of_DWPC	metapath
Lenalidomide—PTGS2—Triamcinolone—atopic dermatitis	0.11	0.193	CbGbCtD
Lenalidomide—PTGS2—Betamethasone—atopic dermatitis	0.0942	0.166	CbGbCtD
Lenalidomide—ABCB1—Tacrolimus—atopic dermatitis	0.0714	0.126	CbGbCtD
Lenalidomide—PTGS2—Dexamethasone—atopic dermatitis	0.0548	0.0965	CbGbCtD
Lenalidomide—ABCB1—Loratadine—atopic dermatitis	0.0523	0.092	CbGbCtD
Lenalidomide—ABCB1—Methylprednisolone—atopic dermatitis	0.0478	0.0841	CbGbCtD
Lenalidomide—ABCB1—Betamethasone—atopic dermatitis	0.0311	0.0547	CbGbCtD
Lenalidomide—ABCB1—Prednisolone—atopic dermatitis	0.0307	0.054	CbGbCtD
Lenalidomide—ABCB1—Hydrocortisone—atopic dermatitis	0.0291	0.0512	CbGbCtD
Lenalidomide—ABCB1—Prednisone—atopic dermatitis	0.029	0.051	CbGbCtD
Lenalidomide—ABCB1—Dexamethasone—atopic dermatitis	0.0181	0.0318	CbGbCtD
Lenalidomide—TNFSF11—RANKL/RANK Signaling Pathway—RELB—atopic dermatitis	0.00845	0.302	CbGpPWpGaD
Lenalidomide—Pomalidomide—TNF—atopic dermatitis	0.00461	0.608	CrCbGaD
Lenalidomide—Thalidomide—TNF—atopic dermatitis	0.00297	0.392	CrCbGaD
Lenalidomide—TNFSF11—Osteoclast Signaling—MAPK8—atopic dermatitis	0.00263	0.0941	CbGpPWpGaD
Lenalidomide—TNFSF11—RANKL/RANK Signaling Pathway—NFKBIA—atopic dermatitis	0.00156	0.0559	CbGpPWpGaD
Lenalidomide—CDH5—S1P2 pathway—MAPK8—atopic dermatitis	0.00135	0.0484	CbGpPWpGaD
Lenalidomide—PTGS2—Fluocinonide—Desonide—atopic dermatitis	0.00122	0.165	CbGdCrCtD
Lenalidomide—TNFSF11—RANKL/RANK Signaling Pathway—MAPK8—atopic dermatitis	0.000981	0.035	CbGpPWpGaD
Lenalidomide—PTGS2—Fluocinonide—Fluocinolone Acetonide—atopic dermatitis	0.000947	0.128	CbGdCrCtD
Lenalidomide—PTGS2—Calcium signaling in the CD4+ TCR pathway—CABIN1—atopic dermatitis	0.000929	0.0332	CbGpPWpGaD
Lenalidomide—PTGS2—Fluocinonide—Mometasone—atopic dermatitis	0.000756	0.102	CbGdCrCtD
Lenalidomide—TNFSF11—IL6-mediated signaling events—IL6—atopic dermatitis	0.00071	0.0254	CbGpPWpGaD
Lenalidomide—TNFSF11—Differentiation Pathway—IL6—atopic dermatitis	0.000698	0.025	CbGpPWpGaD
Lenalidomide—PTGS2—Fluticasone Propionate—Fluocinonide—atopic dermatitis	0.000588	0.0797	CbGdCrCtD
Lenalidomide—PTGS2—Fluticasone Propionate—Fluocinolone Acetonide—atopic dermatitis	0.000571	0.0774	CbGdCrCtD
Lenalidomide—PTGS2—Fluticasone Propionate—Mometasone—atopic dermatitis	0.000456	0.0618	CbGdCrCtD
Lenalidomide—PTGS2—Fluocinonide—Methylprednisolone—atopic dermatitis	0.000451	0.0612	CbGdCrCtD
Lenalidomide—PTGS2—Fluocinonide—Betamethasone—atopic dermatitis	0.000444	0.0602	CbGdCrCtD
Lenalidomide—PTGS2—Fluocinonide—Dexamethasone—atopic dermatitis	0.000444	0.0602	CbGdCrCtD
Lenalidomide—PTGS2—Fluocinonide—Triamcinolone—atopic dermatitis	0.000434	0.0588	CbGdCrCtD
Lenalidomide—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—NFKBIA—atopic dermatitis	0.000429	0.0153	CbGpPWpGaD
Lenalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—FOXP3—atopic dermatitis	0.00042	0.015	CbGpPWpGaD
Lenalidomide—CDH5—Cell-Cell communication—MAPK8—atopic dermatitis	0.000373	0.0133	CbGpPWpGaD
Lenalidomide—PTGS2—Calcium signaling in the CD4+ TCR pathway—IL4—atopic dermatitis	0.000338	0.0121	CbGpPWpGaD
Lenalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL5—atopic dermatitis	0.000308	0.011	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—FCER2—atopic dermatitis	0.0003	0.0107	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—CCL22—atopic dermatitis	0.000279	0.00997	CbGpPWpGaD
Lenalidomide—CDH5—VEGFA-VEGFR2 Pathway—IL6—atopic dermatitis	0.000279	0.00996	CbGpPWpGaD
Lenalidomide—PTGS2—Fluticasone Propionate—Methylprednisolone—atopic dermatitis	0.000272	0.0369	CbGdCrCtD
Lenalidomide—PTGS2—Fluticasone Propionate—Betamethasone—atopic dermatitis	0.000268	0.0363	CbGdCrCtD
Lenalidomide—PTGS2—Fluticasone Propionate—Dexamethasone—atopic dermatitis	0.000268	0.0363	CbGdCrCtD
Lenalidomide—PTGS2—Overview of nanoparticle effects—CXCL8—atopic dermatitis	0.000267	0.00953	CbGpPWpGaD
Lenalidomide—CDH5—Signaling by VEGF—IL6—atopic dermatitis	0.000263	0.0094	CbGpPWpGaD
Lenalidomide—PTGS2—Fluticasone Propionate—Triamcinolone—atopic dermatitis	0.000262	0.0355	CbGdCrCtD
Lenalidomide—CDH5—Signaling Pathways—CCL27—atopic dermatitis	0.000249	0.00888	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—CCL17—atopic dermatitis	0.000223	0.00797	CbGpPWpGaD
Lenalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL4—atopic dermatitis	0.000219	0.00782	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—FOXP3—atopic dermatitis	0.000207	0.00739	CbGpPWpGaD
Lenalidomide—PTGS2—Calcium signaling in the CD4+ TCR pathway—IFNG—atopic dermatitis	0.000205	0.00731	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—KIF3A—atopic dermatitis	0.000199	0.0071	CbGpPWpGaD
Lenalidomide—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARA—atopic dermatitis	0.000188	0.00673	CbGpPWpGaD
Lenalidomide—PTGS2—Overview of nanoparticle effects—TNF—atopic dermatitis	0.000186	0.00664	CbGpPWpGaD
Lenalidomide—PTGS2—Calcium signaling in the CD4+ TCR pathway—IL2—atopic dermatitis	0.000182	0.0065	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—CCL11—atopic dermatitis	0.00018	0.00642	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—CMA1—atopic dermatitis	0.00018	0.00642	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—IL13—atopic dermatitis	0.000177	0.00632	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—STAT6—atopic dermatitis	0.000169	0.00604	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—IL17A—atopic dermatitis	0.000163	0.00581	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—IL5—atopic dermatitis	0.000151	0.00541	CbGpPWpGaD
Lenalidomide—PTGS2—Overview of nanoparticle effects—IL6—atopic dermatitis	0.00015	0.00535	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—CCR3—atopic dermatitis	0.000146	0.00523	CbGpPWpGaD
Lenalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IFNG—atopic dermatitis	0.000132	0.00473	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—CXCL10—atopic dermatitis	0.000132	0.00472	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—TAC1—atopic dermatitis	0.000131	0.00467	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—NPS—atopic dermatitis	0.000131	0.00467	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—CXCR3—atopic dermatitis	0.000128	0.00458	CbGpPWpGaD
Lenalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CXCL8—atopic dermatitis	0.000123	0.0044	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—IL5—atopic dermatitis	0.000121	0.00434	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—BDNF—atopic dermatitis	0.000119	0.00424	CbGpPWpGaD
Lenalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL2—atopic dermatitis	0.000118	0.0042	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—IL10—atopic dermatitis	0.000111	0.00395	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—IL4—atopic dermatitis	0.00011	0.00393	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—IL4—atopic dermatitis	0.000108	0.00384	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—TRPV3—atopic dermatitis	0.000106	0.00378	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—CXCL10—atopic dermatitis	0.000103	0.0037	CbGpPWpGaD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—TNF—atopic dermatitis	9.15e-05	0.00327	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—CCL5—atopic dermatitis	8.91e-05	0.00318	CbGpPWpGaD
Lenalidomide—Loss of consciousness—Triamcinolone—atopic dermatitis	8.66e-05	0.000223	CcSEcCtD
Lenalidomide—Loss of consciousness—Methylprednisolone—atopic dermatitis	8.64e-05	0.000222	CcSEcCtD
Lenalidomide—Rash—Tacrolimus—atopic dermatitis	8.63e-05	0.000222	CcSEcCtD
Lenalidomide—Dermatitis—Tacrolimus—atopic dermatitis	8.63e-05	0.000222	CcSEcCtD
Lenalidomide—Shock—Prednisolone—atopic dermatitis	8.61e-05	0.000221	CcSEcCtD
Lenalidomide—Cough—Triamcinolone—atopic dermatitis	8.6e-05	0.000221	CcSEcCtD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—GLB1—atopic dermatitis	8.59e-05	0.00307	CbGpPWpGaD
Lenalidomide—Headache—Tacrolimus—atopic dermatitis	8.58e-05	0.000221	CcSEcCtD
Lenalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—atopic dermatitis	8.56e-05	0.00306	CbGpPWpGaD
Lenalidomide—Oedema—Hydrocortisone—atopic dermatitis	8.54e-05	0.00022	CcSEcCtD
Lenalidomide—Tachycardia—Prednisolone—atopic dermatitis	8.54e-05	0.00022	CcSEcCtD
Lenalidomide—Hypertension—Triamcinolone—atopic dermatitis	8.51e-05	0.000219	CcSEcCtD
Lenalidomide—Hypertension—Methylprednisolone—atopic dermatitis	8.49e-05	0.000218	CcSEcCtD
Lenalidomide—Infection—Hydrocortisone—atopic dermatitis	8.49e-05	0.000218	CcSEcCtD
Lenalidomide—Hyperhidrosis—Prednisolone—atopic dermatitis	8.46e-05	0.000218	CcSEcCtD
Lenalidomide—PTGS2—C-MYB transcription factor network—CD4—atopic dermatitis	8.44e-05	0.00301	CbGpPWpGaD
Lenalidomide—PTGS2—Selenium Micronutrient Network—IFNG—atopic dermatitis	8.42e-05	0.00301	CbGpPWpGaD
Lenalidomide—Shock—Hydrocortisone—atopic dermatitis	8.41e-05	0.000216	CcSEcCtD
Lenalidomide—Myalgia—Triamcinolone—atopic dermatitis	8.39e-05	0.000216	CcSEcCtD
Lenalidomide—Nervous system disorder—Hydrocortisone—atopic dermatitis	8.38e-05	0.000215	CcSEcCtD
Lenalidomide—Arthralgia—Methylprednisolone—atopic dermatitis	8.37e-05	0.000215	CcSEcCtD
Lenalidomide—Myalgia—Methylprednisolone—atopic dermatitis	8.37e-05	0.000215	CcSEcCtD
Lenalidomide—Eye disorder—Prednisone—atopic dermatitis	8.36e-05	0.000215	CcSEcCtD
Lenalidomide—Anxiety—Methylprednisolone—atopic dermatitis	8.34e-05	0.000215	CcSEcCtD
Lenalidomide—Tachycardia—Hydrocortisone—atopic dermatitis	8.34e-05	0.000214	CcSEcCtD
Lenalidomide—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—atopic dermatitis	8.32e-05	0.000214	CcSEcCtD
Lenalidomide—Flushing—Prednisone—atopic dermatitis	8.3e-05	0.000214	CcSEcCtD
Lenalidomide—Skin disorder—Hydrocortisone—atopic dermatitis	8.3e-05	0.000213	CcSEcCtD
Lenalidomide—Ill-defined disorder—Betamethasone—atopic dermatitis	8.3e-05	0.000213	CcSEcCtD
Lenalidomide—Ill-defined disorder—Dexamethasone—atopic dermatitis	8.3e-05	0.000213	CcSEcCtD
Lenalidomide—Discomfort—Triamcinolone—atopic dermatitis	8.29e-05	0.000213	CcSEcCtD
Lenalidomide—Discomfort—Methylprednisolone—atopic dermatitis	8.27e-05	0.000213	CcSEcCtD
Lenalidomide—Hyperhidrosis—Hydrocortisone—atopic dermatitis	8.26e-05	0.000212	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—NGF—atopic dermatitis	8.25e-05	0.00295	CbGpPWpGaD
Lenalidomide—Dry mouth—Triamcinolone—atopic dermatitis	8.21e-05	0.000211	CcSEcCtD
Lenalidomide—Angioedema—Betamethasone—atopic dermatitis	8.17e-05	0.00021	CcSEcCtD
Lenalidomide—Angioedema—Dexamethasone—atopic dermatitis	8.17e-05	0.00021	CcSEcCtD
Lenalidomide—Anorexia—Hydrocortisone—atopic dermatitis	8.14e-05	0.000209	CcSEcCtD
Lenalidomide—Nausea—Tacrolimus—atopic dermatitis	8.13e-05	0.000209	CcSEcCtD
Lenalidomide—Angiopathy—Prednisone—atopic dermatitis	8.12e-05	0.000209	CcSEcCtD
Lenalidomide—Confusional state—Methylprednisolone—atopic dermatitis	8.09e-05	0.000208	CcSEcCtD
Lenalidomide—Immune system disorder—Prednisone—atopic dermatitis	8.08e-05	0.000208	CcSEcCtD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—BDNF—atopic dermatitis	8.07e-05	0.00288	CbGpPWpGaD
Lenalidomide—Malaise—Dexamethasone—atopic dermatitis	8.06e-05	0.000207	CcSEcCtD
Lenalidomide—Malaise—Betamethasone—atopic dermatitis	8.06e-05	0.000207	CcSEcCtD
Lenalidomide—Oedema—Triamcinolone—atopic dermatitis	8.04e-05	0.000207	CcSEcCtD
Lenalidomide—Vertigo—Dexamethasone—atopic dermatitis	8.04e-05	0.000207	CcSEcCtD
Lenalidomide—Vertigo—Betamethasone—atopic dermatitis	8.04e-05	0.000207	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—CCR5—atopic dermatitis	8.03e-05	0.00287	CbGpPWpGaD
Lenalidomide—Syncope—Dexamethasone—atopic dermatitis	8.02e-05	0.000206	CcSEcCtD
Lenalidomide—Syncope—Betamethasone—atopic dermatitis	8.02e-05	0.000206	CcSEcCtD
Lenalidomide—Arrhythmia—Prednisone—atopic dermatitis	7.99e-05	0.000206	CcSEcCtD
Lenalidomide—Infection—Triamcinolone—atopic dermatitis	7.99e-05	0.000206	CcSEcCtD
Lenalidomide—Hypotension—Hydrocortisone—atopic dermatitis	7.98e-05	0.000205	CcSEcCtD
Lenalidomide—Infection—Methylprednisolone—atopic dermatitis	7.97e-05	0.000205	CcSEcCtD
Lenalidomide—Shock—Triamcinolone—atopic dermatitis	7.91e-05	0.000204	CcSEcCtD
Lenalidomide—Insomnia—Prednisolone—atopic dermatitis	7.91e-05	0.000203	CcSEcCtD
Lenalidomide—Alopecia—Prednisone—atopic dermatitis	7.91e-05	0.000203	CcSEcCtD
Lenalidomide—Shock—Methylprednisolone—atopic dermatitis	7.9e-05	0.000203	CcSEcCtD
Lenalidomide—Nervous system disorder—Methylprednisolone—atopic dermatitis	7.87e-05	0.000202	CcSEcCtD
Lenalidomide—Loss of consciousness—Dexamethasone—atopic dermatitis	7.86e-05	0.000202	CcSEcCtD
Lenalidomide—Loss of consciousness—Betamethasone—atopic dermatitis	7.86e-05	0.000202	CcSEcCtD
Lenalidomide—Paraesthesia—Prednisolone—atopic dermatitis	7.85e-05	0.000202	CcSEcCtD
Lenalidomide—Tachycardia—Triamcinolone—atopic dermatitis	7.85e-05	0.000202	CcSEcCtD
Lenalidomide—Mental disorder—Prednisone—atopic dermatitis	7.84e-05	0.000202	CcSEcCtD
Lenalidomide—Tachycardia—Methylprednisolone—atopic dermatitis	7.83e-05	0.000201	CcSEcCtD
Lenalidomide—Skin disorder—Methylprednisolone—atopic dermatitis	7.8e-05	0.000201	CcSEcCtD
Lenalidomide—Erythema—Prednisone—atopic dermatitis	7.79e-05	0.0002	CcSEcCtD
Lenalidomide—Malnutrition—Prednisone—atopic dermatitis	7.79e-05	0.0002	CcSEcCtD
Lenalidomide—Musculoskeletal discomfort—Hydrocortisone—atopic dermatitis	7.78e-05	0.0002	CcSEcCtD
Lenalidomide—Hyperhidrosis—Triamcinolone—atopic dermatitis	7.78e-05	0.0002	CcSEcCtD
Lenalidomide—Hyperhidrosis—Methylprednisolone—atopic dermatitis	7.76e-05	0.0002	CcSEcCtD
Lenalidomide—Insomnia—Hydrocortisone—atopic dermatitis	7.73e-05	0.000199	CcSEcCtD
Lenalidomide—Hypertension—Betamethasone—atopic dermatitis	7.72e-05	0.000199	CcSEcCtD
Lenalidomide—Hypertension—Dexamethasone—atopic dermatitis	7.72e-05	0.000199	CcSEcCtD
Lenalidomide—Paraesthesia—Hydrocortisone—atopic dermatitis	7.67e-05	0.000197	CcSEcCtD
Lenalidomide—ABCB1—Allograft Rejection—CASP8—atopic dermatitis	7.65e-05	0.00273	CbGpPWpGaD
Lenalidomide—Myalgia—Betamethasone—atopic dermatitis	7.61e-05	0.000196	CcSEcCtD
Lenalidomide—Myalgia—Dexamethasone—atopic dermatitis	7.61e-05	0.000196	CcSEcCtD
Lenalidomide—Anxiety—Dexamethasone—atopic dermatitis	7.59e-05	0.000195	CcSEcCtD
Lenalidomide—Anxiety—Betamethasone—atopic dermatitis	7.59e-05	0.000195	CcSEcCtD
Lenalidomide—Discomfort—Dexamethasone—atopic dermatitis	7.52e-05	0.000193	CcSEcCtD
Lenalidomide—Discomfort—Betamethasone—atopic dermatitis	7.52e-05	0.000193	CcSEcCtD
Lenalidomide—Dyspepsia—Hydrocortisone—atopic dermatitis	7.52e-05	0.000193	CcSEcCtD
Lenalidomide—PTGS2—Selenium Micronutrient Network—IL1B—atopic dermatitis	7.51e-05	0.00268	CbGpPWpGaD
Lenalidomide—Hypotension—Methylprednisolone—atopic dermatitis	7.5e-05	0.000193	CcSEcCtD
Lenalidomide—Pain—Prednisolone—atopic dermatitis	7.48e-05	0.000192	CcSEcCtD
Lenalidomide—Decreased appetite—Hydrocortisone—atopic dermatitis	7.43e-05	0.000191	CcSEcCtD
Lenalidomide—Gastrointestinal disorder—Hydrocortisone—atopic dermatitis	7.38e-05	0.00019	CcSEcCtD
Lenalidomide—Fatigue—Hydrocortisone—atopic dermatitis	7.37e-05	0.000189	CcSEcCtD
Lenalidomide—Vision blurred—Prednisone—atopic dermatitis	7.34e-05	0.000189	CcSEcCtD
Lenalidomide—Musculoskeletal discomfort—Triamcinolone—atopic dermatitis	7.33e-05	0.000189	CcSEcCtD
Lenalidomide—Musculoskeletal discomfort—Methylprednisolone—atopic dermatitis	7.31e-05	0.000188	CcSEcCtD
Lenalidomide—Pain—Hydrocortisone—atopic dermatitis	7.31e-05	0.000188	CcSEcCtD
Lenalidomide—Oedema—Betamethasone—atopic dermatitis	7.3e-05	0.000188	CcSEcCtD
Lenalidomide—Oedema—Dexamethasone—atopic dermatitis	7.3e-05	0.000188	CcSEcCtD
Lenalidomide—Insomnia—Triamcinolone—atopic dermatitis	7.28e-05	0.000187	CcSEcCtD
Lenalidomide—Insomnia—Methylprednisolone—atopic dermatitis	7.26e-05	0.000187	CcSEcCtD
Lenalidomide—Infection—Dexamethasone—atopic dermatitis	7.25e-05	0.000187	CcSEcCtD
Lenalidomide—Infection—Betamethasone—atopic dermatitis	7.25e-05	0.000187	CcSEcCtD
Lenalidomide—Ill-defined disorder—Prednisone—atopic dermatitis	7.23e-05	0.000186	CcSEcCtD
Lenalidomide—Paraesthesia—Triamcinolone—atopic dermatitis	7.22e-05	0.000186	CcSEcCtD
Lenalidomide—Feeling abnormal—Prednisolone—atopic dermatitis	7.21e-05	0.000185	CcSEcCtD
Lenalidomide—Paraesthesia—Methylprednisolone—atopic dermatitis	7.21e-05	0.000185	CcSEcCtD
Lenalidomide—Anaemia—Prednisone—atopic dermatitis	7.2e-05	0.000185	CcSEcCtD
Lenalidomide—Shock—Dexamethasone—atopic dermatitis	7.18e-05	0.000185	CcSEcCtD
Lenalidomide—Shock—Betamethasone—atopic dermatitis	7.18e-05	0.000185	CcSEcCtD
Lenalidomide—Dyspnoea—Triamcinolone—atopic dermatitis	7.17e-05	0.000184	CcSEcCtD
Lenalidomide—Nervous system disorder—Dexamethasone—atopic dermatitis	7.16e-05	0.000184	CcSEcCtD
Lenalidomide—Nervous system disorder—Betamethasone—atopic dermatitis	7.16e-05	0.000184	CcSEcCtD
Lenalidomide—Agitation—Prednisone—atopic dermatitis	7.16e-05	0.000184	CcSEcCtD
Lenalidomide—Thrombocytopenia—Betamethasone—atopic dermatitis	7.15e-05	0.000184	CcSEcCtD
Lenalidomide—Thrombocytopenia—Dexamethasone—atopic dermatitis	7.15e-05	0.000184	CcSEcCtD
Lenalidomide—Tachycardia—Dexamethasone—atopic dermatitis	7.12e-05	0.000183	CcSEcCtD
Lenalidomide—Tachycardia—Betamethasone—atopic dermatitis	7.12e-05	0.000183	CcSEcCtD
Lenalidomide—Angioedema—Prednisone—atopic dermatitis	7.12e-05	0.000183	CcSEcCtD
Lenalidomide—Dyspepsia—Triamcinolone—atopic dermatitis	7.08e-05	0.000182	CcSEcCtD
Lenalidomide—Dyspepsia—Methylprednisolone—atopic dermatitis	7.07e-05	0.000182	CcSEcCtD
Lenalidomide—Hyperhidrosis—Betamethasone—atopic dermatitis	7.06e-05	0.000181	CcSEcCtD
Lenalidomide—Hyperhidrosis—Dexamethasone—atopic dermatitis	7.06e-05	0.000181	CcSEcCtD
Lenalidomide—Feeling abnormal—Hydrocortisone—atopic dermatitis	7.04e-05	0.000181	CcSEcCtD
Lenalidomide—Malaise—Prednisone—atopic dermatitis	7.02e-05	0.000181	CcSEcCtD
Lenalidomide—Vertigo—Prednisone—atopic dermatitis	7e-05	0.00018	CcSEcCtD
Lenalidomide—Gastrointestinal pain—Hydrocortisone—atopic dermatitis	6.99e-05	0.00018	CcSEcCtD
Lenalidomide—Syncope—Prednisone—atopic dermatitis	6.98e-05	0.00018	CcSEcCtD
Lenalidomide—Anorexia—Betamethasone—atopic dermatitis	6.96e-05	0.000179	CcSEcCtD
Lenalidomide—Anorexia—Dexamethasone—atopic dermatitis	6.96e-05	0.000179	CcSEcCtD
Lenalidomide—Urticaria—Prednisolone—atopic dermatitis	6.95e-05	0.000179	CcSEcCtD
Lenalidomide—Fatigue—Triamcinolone—atopic dermatitis	6.94e-05	0.000178	CcSEcCtD
Lenalidomide—Fatigue—Methylprednisolone—atopic dermatitis	6.92e-05	0.000178	CcSEcCtD
Lenalidomide—Pain—Triamcinolone—atopic dermatitis	6.88e-05	0.000177	CcSEcCtD
Lenalidomide—Loss of consciousness—Prednisone—atopic dermatitis	6.85e-05	0.000176	CcSEcCtD
Lenalidomide—Hypotension—Dexamethasone—atopic dermatitis	6.82e-05	0.000175	CcSEcCtD
Lenalidomide—Hypotension—Betamethasone—atopic dermatitis	6.82e-05	0.000175	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—NFKBIA—atopic dermatitis	6.8e-05	0.00243	CbGpPWpGaD
Lenalidomide—Urticaria—Hydrocortisone—atopic dermatitis	6.79e-05	0.000175	CcSEcCtD
Lenalidomide—Body temperature increased—Hydrocortisone—atopic dermatitis	6.75e-05	0.000174	CcSEcCtD
Lenalidomide—Abdominal pain—Hydrocortisone—atopic dermatitis	6.75e-05	0.000174	CcSEcCtD
Lenalidomide—Hypertension—Prednisone—atopic dermatitis	6.72e-05	0.000173	CcSEcCtD
Lenalidomide—PTGS2—Spinal Cord Injury—IFNG—atopic dermatitis	6.66e-05	0.00238	CbGpPWpGaD
Lenalidomide—Musculoskeletal discomfort—Dexamethasone—atopic dermatitis	6.65e-05	0.000171	CcSEcCtD
Lenalidomide—Musculoskeletal discomfort—Betamethasone—atopic dermatitis	6.65e-05	0.000171	CcSEcCtD
Lenalidomide—Arthralgia—Prednisone—atopic dermatitis	6.63e-05	0.000171	CcSEcCtD
Lenalidomide—Myalgia—Prednisone—atopic dermatitis	6.63e-05	0.000171	CcSEcCtD
Lenalidomide—Feeling abnormal—Triamcinolone—atopic dermatitis	6.63e-05	0.00017	CcSEcCtD
Lenalidomide—Feeling abnormal—Methylprednisolone—atopic dermatitis	6.61e-05	0.00017	CcSEcCtD
Lenalidomide—Anxiety—Prednisone—atopic dermatitis	6.61e-05	0.00017	CcSEcCtD
Lenalidomide—Insomnia—Betamethasone—atopic dermatitis	6.6e-05	0.00017	CcSEcCtD
Lenalidomide—Insomnia—Dexamethasone—atopic dermatitis	6.6e-05	0.00017	CcSEcCtD
Lenalidomide—Unspecified disorder of skin and subcutaneous tissue—Prednisone—atopic dermatitis	6.59e-05	0.000169	CcSEcCtD
Lenalidomide—Gastrointestinal pain—Methylprednisolone—atopic dermatitis	6.56e-05	0.000169	CcSEcCtD
Lenalidomide—Paraesthesia—Dexamethasone—atopic dermatitis	6.55e-05	0.000169	CcSEcCtD
Lenalidomide—Paraesthesia—Betamethasone—atopic dermatitis	6.55e-05	0.000169	CcSEcCtD
Lenalidomide—Discomfort—Prednisone—atopic dermatitis	6.55e-05	0.000169	CcSEcCtD
Lenalidomide—ABCB1—Allograft Rejection—IFNG—atopic dermatitis	6.5e-05	0.00232	CbGpPWpGaD
Lenalidomide—Hypersensitivity—Prednisolone—atopic dermatitis	6.44e-05	0.000166	CcSEcCtD
Lenalidomide—Dyspepsia—Dexamethasone—atopic dermatitis	6.42e-05	0.000165	CcSEcCtD
Lenalidomide—Dyspepsia—Betamethasone—atopic dermatitis	6.42e-05	0.000165	CcSEcCtD
Lenalidomide—Urticaria—Triamcinolone—atopic dermatitis	6.39e-05	0.000164	CcSEcCtD
Lenalidomide—Urticaria—Methylprednisolone—atopic dermatitis	6.38e-05	0.000164	CcSEcCtD
Lenalidomide—Body temperature increased—Triamcinolone—atopic dermatitis	6.36e-05	0.000164	CcSEcCtD
Lenalidomide—Oedema—Prednisone—atopic dermatitis	6.36e-05	0.000163	CcSEcCtD
Lenalidomide—Abdominal pain—Methylprednisolone—atopic dermatitis	6.34e-05	0.000163	CcSEcCtD
Lenalidomide—Decreased appetite—Dexamethasone—atopic dermatitis	6.34e-05	0.000163	CcSEcCtD
Lenalidomide—Decreased appetite—Betamethasone—atopic dermatitis	6.34e-05	0.000163	CcSEcCtD
Lenalidomide—Infection—Prednisone—atopic dermatitis	6.31e-05	0.000162	CcSEcCtD
Lenalidomide—Gastrointestinal disorder—Betamethasone—atopic dermatitis	6.3e-05	0.000162	CcSEcCtD
Lenalidomide—Gastrointestinal disorder—Dexamethasone—atopic dermatitis	6.3e-05	0.000162	CcSEcCtD
Lenalidomide—Hypersensitivity—Hydrocortisone—atopic dermatitis	6.29e-05	0.000162	CcSEcCtD
Lenalidomide—Fatigue—Betamethasone—atopic dermatitis	6.29e-05	0.000162	CcSEcCtD
Lenalidomide—Fatigue—Dexamethasone—atopic dermatitis	6.29e-05	0.000162	CcSEcCtD
Lenalidomide—Shock—Prednisone—atopic dermatitis	6.25e-05	0.000161	CcSEcCtD
Lenalidomide—Pain—Dexamethasone—atopic dermatitis	6.24e-05	0.000161	CcSEcCtD
Lenalidomide—Pain—Betamethasone—atopic dermatitis	6.24e-05	0.000161	CcSEcCtD
Lenalidomide—Nervous system disorder—Prednisone—atopic dermatitis	6.23e-05	0.00016	CcSEcCtD
Lenalidomide—Tachycardia—Prednisone—atopic dermatitis	6.2e-05	0.00016	CcSEcCtD
Lenalidomide—PTGS2—Spinal Cord Injury—CXCL8—atopic dermatitis	6.19e-05	0.00221	CbGpPWpGaD
Lenalidomide—Skin disorder—Prednisone—atopic dermatitis	6.17e-05	0.000159	CcSEcCtD
Lenalidomide—Hyperhidrosis—Prednisone—atopic dermatitis	6.14e-05	0.000158	CcSEcCtD
Lenalidomide—Asthenia—Hydrocortisone—atopic dermatitis	6.13e-05	0.000158	CcSEcCtD
Lenalidomide—Anorexia—Prednisone—atopic dermatitis	6.06e-05	0.000156	CcSEcCtD
Lenalidomide—ABCB1—Allograft Rejection—CXCL8—atopic dermatitis	6.05e-05	0.00216	CbGpPWpGaD
Lenalidomide—Pruritus—Hydrocortisone—atopic dermatitis	6.04e-05	0.000155	CcSEcCtD
Lenalidomide—Feeling abnormal—Dexamethasone—atopic dermatitis	6.01e-05	0.000155	CcSEcCtD
Lenalidomide—Feeling abnormal—Betamethasone—atopic dermatitis	6.01e-05	0.000155	CcSEcCtD
Lenalidomide—Gastrointestinal pain—Betamethasone—atopic dermatitis	5.97e-05	0.000154	CcSEcCtD
Lenalidomide—Gastrointestinal pain—Dexamethasone—atopic dermatitis	5.97e-05	0.000154	CcSEcCtD
Lenalidomide—PTGS2—Spinal Cord Injury—IL1B—atopic dermatitis	5.94e-05	0.00212	CbGpPWpGaD
Lenalidomide—Hypersensitivity—Triamcinolone—atopic dermatitis	5.93e-05	0.000152	CcSEcCtD
Lenalidomide—PTGS2—Spinal Cord Injury—IL2—atopic dermatitis	5.91e-05	0.00211	CbGpPWpGaD
Lenalidomide—Hypersensitivity—Methylprednisolone—atopic dermatitis	5.91e-05	0.000152	CcSEcCtD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—NFKBIA—atopic dermatitis	5.9e-05	0.00211	CbGpPWpGaD
Lenalidomide—Diarrhoea—Hydrocortisone—atopic dermatitis	5.85e-05	0.00015	CcSEcCtD
Lenalidomide—ABCB1—Allograft Rejection—IL1B—atopic dermatitis	5.8e-05	0.00207	CbGpPWpGaD
Lenalidomide—Urticaria—Dexamethasone—atopic dermatitis	5.8e-05	0.000149	CcSEcCtD
Lenalidomide—Urticaria—Betamethasone—atopic dermatitis	5.8e-05	0.000149	CcSEcCtD
Lenalidomide—Musculoskeletal discomfort—Prednisone—atopic dermatitis	5.79e-05	0.000149	CcSEcCtD
Lenalidomide—Dizziness—Prednisolone—atopic dermatitis	5.78e-05	0.000149	CcSEcCtD
Lenalidomide—ABCB1—Allograft Rejection—IL2—atopic dermatitis	5.78e-05	0.00207	CbGpPWpGaD
Lenalidomide—Asthenia—Triamcinolone—atopic dermatitis	5.77e-05	0.000148	CcSEcCtD
Lenalidomide—Body temperature increased—Betamethasone—atopic dermatitis	5.77e-05	0.000148	CcSEcCtD
Lenalidomide—Body temperature increased—Dexamethasone—atopic dermatitis	5.77e-05	0.000148	CcSEcCtD
Lenalidomide—Abdominal pain—Betamethasone—atopic dermatitis	5.77e-05	0.000148	CcSEcCtD
Lenalidomide—Abdominal pain—Dexamethasone—atopic dermatitis	5.77e-05	0.000148	CcSEcCtD
Lenalidomide—Asthenia—Methylprednisolone—atopic dermatitis	5.76e-05	0.000148	CcSEcCtD
Lenalidomide—Insomnia—Prednisone—atopic dermatitis	5.75e-05	0.000148	CcSEcCtD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—BDNF—atopic dermatitis	5.72e-05	0.00204	CbGpPWpGaD
Lenalidomide—Paraesthesia—Prednisone—atopic dermatitis	5.71e-05	0.000147	CcSEcCtD
Lenalidomide—Pruritus—Triamcinolone—atopic dermatitis	5.69e-05	0.000146	CcSEcCtD
Lenalidomide—Pruritus—Methylprednisolone—atopic dermatitis	5.68e-05	0.000146	CcSEcCtD
Lenalidomide—Dizziness—Hydrocortisone—atopic dermatitis	5.65e-05	0.000145	CcSEcCtD
Lenalidomide—Dyspepsia—Prednisone—atopic dermatitis	5.6e-05	0.000144	CcSEcCtD
Lenalidomide—Decreased appetite—Prednisone—atopic dermatitis	5.53e-05	0.000142	CcSEcCtD
Lenalidomide—Rash—Prednisolone—atopic dermatitis	5.52e-05	0.000142	CcSEcCtD
Lenalidomide—Dermatitis—Prednisolone—atopic dermatitis	5.51e-05	0.000142	CcSEcCtD
Lenalidomide—Diarrhoea—Methylprednisolone—atopic dermatitis	5.49e-05	0.000141	CcSEcCtD
Lenalidomide—Fatigue—Prednisone—atopic dermatitis	5.48e-05	0.000141	CcSEcCtD
Lenalidomide—Headache—Prednisolone—atopic dermatitis	5.48e-05	0.000141	CcSEcCtD
Lenalidomide—PTGS2—Selenium Micronutrient Network—TNF—atopic dermatitis	5.45e-05	0.00195	CbGpPWpGaD
Lenalidomide—Constipation—Prednisone—atopic dermatitis	5.44e-05	0.00014	CcSEcCtD
Lenalidomide—Vomiting—Hydrocortisone—atopic dermatitis	5.43e-05	0.00014	CcSEcCtD
Lenalidomide—Rash—Hydrocortisone—atopic dermatitis	5.39e-05	0.000139	CcSEcCtD
Lenalidomide—Dermatitis—Hydrocortisone—atopic dermatitis	5.38e-05	0.000138	CcSEcCtD
Lenalidomide—Headache—Hydrocortisone—atopic dermatitis	5.35e-05	0.000138	CcSEcCtD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CASP8—atopic dermatitis	5.32e-05	0.0019	CbGpPWpGaD
Lenalidomide—Dizziness—Triamcinolone—atopic dermatitis	5.32e-05	0.000137	CcSEcCtD
Lenalidomide—Dizziness—Methylprednisolone—atopic dermatitis	5.31e-05	0.000137	CcSEcCtD
Lenalidomide—Feeling abnormal—Prednisone—atopic dermatitis	5.24e-05	0.000135	CcSEcCtD
Lenalidomide—Asthenia—Betamethasone—atopic dermatitis	5.24e-05	0.000135	CcSEcCtD
Lenalidomide—Asthenia—Dexamethasone—atopic dermatitis	5.24e-05	0.000135	CcSEcCtD
Lenalidomide—Gastrointestinal pain—Prednisone—atopic dermatitis	5.2e-05	0.000134	CcSEcCtD
Lenalidomide—Nausea—Prednisolone—atopic dermatitis	5.2e-05	0.000134	CcSEcCtD
Lenalidomide—Pruritus—Dexamethasone—atopic dermatitis	5.16e-05	0.000133	CcSEcCtD
Lenalidomide—Pruritus—Betamethasone—atopic dermatitis	5.16e-05	0.000133	CcSEcCtD
Lenalidomide—Vomiting—Triamcinolone—atopic dermatitis	5.11e-05	0.000132	CcSEcCtD
Lenalidomide—Vomiting—Methylprednisolone—atopic dermatitis	5.1e-05	0.000131	CcSEcCtD
Lenalidomide—Nausea—Hydrocortisone—atopic dermatitis	5.07e-05	0.000131	CcSEcCtD
Lenalidomide—Rash—Triamcinolone—atopic dermatitis	5.07e-05	0.00013	CcSEcCtD
Lenalidomide—Dermatitis—Triamcinolone—atopic dermatitis	5.07e-05	0.00013	CcSEcCtD
Lenalidomide—Rash—Methylprednisolone—atopic dermatitis	5.06e-05	0.00013	CcSEcCtD
Lenalidomide—Dermatitis—Methylprednisolone—atopic dermatitis	5.06e-05	0.00013	CcSEcCtD
Lenalidomide—Urticaria—Prednisone—atopic dermatitis	5.05e-05	0.00013	CcSEcCtD
Lenalidomide—Headache—Triamcinolone—atopic dermatitis	5.04e-05	0.00013	CcSEcCtD
Lenalidomide—Headache—Methylprednisolone—atopic dermatitis	5.03e-05	0.000129	CcSEcCtD
Lenalidomide—Abdominal pain—Prednisone—atopic dermatitis	5.02e-05	0.000129	CcSEcCtD
Lenalidomide—Body temperature increased—Prednisone—atopic dermatitis	5.02e-05	0.000129	CcSEcCtD
Lenalidomide—Diarrhoea—Dexamethasone—atopic dermatitis	4.99e-05	0.000128	CcSEcCtD
Lenalidomide—Diarrhoea—Betamethasone—atopic dermatitis	4.99e-05	0.000128	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—CXCL8—atopic dermatitis	4.85e-05	0.00173	CbGpPWpGaD
Lenalidomide—Dizziness—Betamethasone—atopic dermatitis	4.83e-05	0.000124	CcSEcCtD
Lenalidomide—Dizziness—Dexamethasone—atopic dermatitis	4.83e-05	0.000124	CcSEcCtD
Lenalidomide—Nausea—Triamcinolone—atopic dermatitis	4.78e-05	0.000123	CcSEcCtD
Lenalidomide—Nausea—Methylprednisolone—atopic dermatitis	4.77e-05	0.000123	CcSEcCtD
Lenalidomide—Hypersensitivity—Prednisone—atopic dermatitis	4.68e-05	0.00012	CcSEcCtD
Lenalidomide—Vomiting—Betamethasone—atopic dermatitis	4.64e-05	0.000119	CcSEcCtD
Lenalidomide—Vomiting—Dexamethasone—atopic dermatitis	4.64e-05	0.000119	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—IL2—atopic dermatitis	4.64e-05	0.00166	CbGpPWpGaD
Lenalidomide—Rash—Dexamethasone—atopic dermatitis	4.6e-05	0.000118	CcSEcCtD
Lenalidomide—Rash—Betamethasone—atopic dermatitis	4.6e-05	0.000118	CcSEcCtD
Lenalidomide—Dermatitis—Dexamethasone—atopic dermatitis	4.6e-05	0.000118	CcSEcCtD
Lenalidomide—Dermatitis—Betamethasone—atopic dermatitis	4.6e-05	0.000118	CcSEcCtD
Lenalidomide—Headache—Betamethasone—atopic dermatitis	4.57e-05	0.000118	CcSEcCtD
Lenalidomide—Headache—Dexamethasone—atopic dermatitis	4.57e-05	0.000118	CcSEcCtD
Lenalidomide—PTGS2—Disease—GLB1—atopic dermatitis	4.57e-05	0.00163	CbGpPWpGaD
Lenalidomide—Asthenia—Prednisone—atopic dermatitis	4.56e-05	0.000117	CcSEcCtD
Lenalidomide—Pruritus—Prednisone—atopic dermatitis	4.5e-05	0.000116	CcSEcCtD
Lenalidomide—PTGS2—Selenium Micronutrient Network—IL6—atopic dermatitis	4.4e-05	0.00157	CbGpPWpGaD
Lenalidomide—Diarrhoea—Prednisone—atopic dermatitis	4.35e-05	0.000112	CcSEcCtD
Lenalidomide—Nausea—Dexamethasone—atopic dermatitis	4.34e-05	0.000112	CcSEcCtD
Lenalidomide—Nausea—Betamethasone—atopic dermatitis	4.34e-05	0.000112	CcSEcCtD
Lenalidomide—PTGS2—Spinal Cord Injury—TNF—atopic dermatitis	4.31e-05	0.00154	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—MAPK8—atopic dermatitis	4.27e-05	0.00153	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—TNF—atopic dermatitis	4.21e-05	0.0015	CbGpPWpGaD
Lenalidomide—Dizziness—Prednisone—atopic dermatitis	4.2e-05	0.000108	CcSEcCtD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—NFKBIA—atopic dermatitis	4.18e-05	0.0015	CbGpPWpGaD
Lenalidomide—Vomiting—Prednisone—atopic dermatitis	4.04e-05	0.000104	CcSEcCtD
Lenalidomide—Rash—Prednisone—atopic dermatitis	4.01e-05	0.000103	CcSEcCtD
Lenalidomide—Dermatitis—Prednisone—atopic dermatitis	4e-05	0.000103	CcSEcCtD
Lenalidomide—Headache—Prednisone—atopic dermatitis	3.98e-05	0.000102	CcSEcCtD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—SLC11A1—atopic dermatitis	3.88e-05	0.00139	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—GLB1—atopic dermatitis	3.83e-05	0.00137	CbGpPWpGaD
Lenalidomide—Nausea—Prednisone—atopic dermatitis	3.78e-05	9.71e-05	CcSEcCtD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CASP8—atopic dermatitis	3.77e-05	0.00135	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—MAPK8—atopic dermatitis	3.7e-05	0.00132	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—ADSL—atopic dermatitis	3.67e-05	0.00131	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—IL6—atopic dermatitis	3.48e-05	0.00124	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—SLC11A1—atopic dermatitis	3.06e-05	0.00109	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—atopic dermatitis	2.93e-05	0.00105	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—PPARA—atopic dermatitis	2.79e-05	0.000996	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—IL6—atopic dermatitis	2.73e-05	0.000974	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—GLB1—atopic dermatitis	2.71e-05	0.000969	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK8—atopic dermatitis	2.63e-05	0.000938	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—ADSL—atopic dermatitis	2.6e-05	0.000929	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—atopic dermatitis	2.08e-05	0.000742	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—PPARA—atopic dermatitis	1.88e-05	0.000671	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—CCR5—atopic dermatitis	1.55e-05	0.000553	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—PPARA—atopic dermatitis	1.24e-05	0.000444	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—CD4—atopic dermatitis	9.71e-06	0.000347	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PPARA—atopic dermatitis	8.8e-06	0.000314	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—IL6—atopic dermatitis	5.25e-06	0.000188	CbGpPWpGaD
